March 25, 2020 / 7:19 AM / 7 days ago

BRIEF-Biophytis Completes Recruitment of SARA-INT Phase 2b Study

March 25 (Reuters) - BIOPHYTIS SA:

* ANNOUNCED ON TUESDAY IT HAS COMPLETED ENROLLMENT OF THE 231 PATIENTS INTO ITS SARA-INT PHASE 2B STUDY

* STUDY SEEES TO EVALUATE THE SAFETY AND EFFICACY OF ITS LEAD DRUG CANDIDATE SARCONEOS (BIO101) FOR THE TREATMENT OF NEUROMUSCULAR DISEASES

* SARCONEOS (BIO101) WILL BE ADMINISTERED ORALLY IN TWO DOSES IN PATIENTS WITH SARCOPENIA AT RISK OF MOBILITY DISABILITY

* THE PRIMARY ENDPOINT IT THE GAIT-SPEED OVER THE 400-METER WALK TEST (400MWT)TO MEASURE THE PARTICIPANT’S MOBILITY FUNCTION

* PROTOCOL ADAPTED TO ALLOW PATIENT FOLLOW-UP TO TAKE PLACE AT HOME DUE TO COVID-19

Source text: bit.ly/2UeAytU

Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below